Aura Biosciences (AURA) News
NASDAQ: AURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
6.87-0.11 (-1.58%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AURA news summary
We found 6 recent headlines mentioning Aura Biosciences (AURA): 2 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, AURA is down 1.58% at $6.87. The most recent story, "OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate", was published by GlobeNewswire on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Aura Biosciences headlines
- OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidateOxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc.…GlobeNewswire
- Oxford Biomedica Confirms Aura Biosciences Partnership For Phase 3 Eye Cancer Drug Manufacturing(RTTNews) - Oxford Biomedica plc (OXB.L), a gene and cell therapy company, on Tuesday confirmed its manufacturing and supply partnership with Aura Biosciences, Inc. (AURA), a biotechnology company.Nasdaq
- Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsAura Biosciences, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline. The company's Phase 3 CoMpass trial of belzupacap…Nasdaq
- Aura Biosciences GAAP EPS of -$0.29Seeking Alpha
- Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPhase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visitsGlobeNewswire
- Aura Biosciences to Participate in Upcoming Investor ConferenceAura Biosciences President and CEO, Natalie Holles, will present at the upcoming Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026.GlobeNewswire